GPCR
NASDAQStructure Therapeutics Inc.
Structure Therapeutics Inc. (GPCR) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for GPCR, including 2 press releases and news items, 2 SEC filings and 1 13D/G filing. The most recent was published Nov 9, 2026.
GPCR rankings
Financial highlights
Full financials- Net income, TTM
- -$214.84M
- Free cash flow, TTM
- -$224.59M
- Cash
- $272.64M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks31+500%
2026-05-172026-11-08
Mix1290d
- Insider3(25%)
- Other3(25%)
- SEC Filings3(25%)
- Earnings2(17%)
- 13D/G1(8%)
Activity · 52 weeks7938 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Structure Therapeutics Inc.10-Q - Structure Therapeutics Inc. (0001888886) (Filer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsPhase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies Reported Phase 1 SAD data for ACCG-2671 (oral small molecule amylin receptor agonist),demonstrating a ~6-day half-life and no serious adverse events; MAD clinical trial dosing underway, with topline data expected in 1H 2027 Cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026expected to fund projected operations and key clinical milestones through 2028 SAN FRAN
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)
- PRStructure Therapeutics to Participate in the Jefferies Global Healthcare ConferenceSAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced that management will participate in the Jefferies Global Healthcare Conference being held November 16-19, 2026 in London, UK. Jefferies Global Healthcare ConferenceDate: Tuesday, November 17Format: Fireside chat and 1x1 meetingsTime: 12:00 PM GMTLocation: London, UK The live and archived webcasts will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and replays will be
- PRStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD. Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label ExtensionDate/Time: November 15, 2026, 2:30 p.m. – 3:30 p.m. ETLocation: Exhibit Hall BCD Title: Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for
- INSIDERCHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 10,626 units of Ordinary Shares, decreasing direct ownership by 8% to 258,228 units (SEC Form 4) (for tax liability)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight ManagementACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027 Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates due to adverse events in the ACCESS OLE clinical trial ACCOMPLISH-1 an
- PRStructure Therapeutics to Participate in Upcoming Healthcare Investor ConferencesSAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September: 2026 Cantor Global Healthcare ConferenceDate: Thursday, September 10Format: Fireside chat and 1x1 meetingsTime: 3:55 – 4:25 PM EDTLocation: New York, NY Morgan Stanley 24th Annual Global Healthcare ConferenceDate: Wednesday, September 16Format: Fireside chat and 1x1 meetingsTime: 10:45 – 11:20 AM EDTLocation: New York, NY Bernstein’s 3rd Annual H
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 17,817 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 11,817 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERChief Commercial Officer Berrios John Joseph was granted 140,766 units of Ordinary Shares (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 3 filed by new insider Berrios John Joseph3 - Structure Therapeutics Inc. (0001888886) (Issuer)
- SECSEC Form 10-Q filed by Structure Therapeutics Inc.10-Q - Structure Therapeutics Inc. (0001888886) (Filer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsFirst patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on track for Q3 2026 Topline 72-week aleniglipron ACCESS OLE data on track for Q3 2026; data from body composition, type 2 diabetes/obesity and SWITCH clinical trials on track for Q4 2026 Appointed metabolic commercial industry veteran John Berrios as Chief Commercial Officer Cash, cash equivalents and short-term investments of $1.3 billion as of June 30, 2026 expected to fund projected operations an
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 11,817 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by See Remark 1 Fmr Llc4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 23,634 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen exercised 23,634 units of Ordinary Shares at a strike of $0.34 (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Director Russell Angus C.4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Director Love Ted W4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Director Waldstreicher Joanne4 - Structure Therapeutics Inc. (0001888886) (Issuer)
GPCR FAQ
9 questionsWhat is the latest news on GPCR?
In the last 30 days Quantisnow tracked 6 wire items for GPCR: 2 press releases and news items, 2 SEC filings, 1 13D/G filing and 1 earnings update. The most recent was published on November 9, 2026.Is GPCR profitable?
No. Structure Therapeutics Inc. reported a net loss of $214.84M for the twelve months ended Jun 30, 2026.How much cash and debt does GPCR have?
Structure Therapeutics Inc. reported $272.64M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does GPCR stock trade?
Structure Therapeutics Inc. (GPCR) is listed on NASDAQ.What sector and industry is GPCR in?
Structure Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Structure Therapeutics Inc. go public?
Structure Therapeutics Inc. (GPCR) completed its IPO in 2023.What are analysts saying about GPCR?
Structure Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $101.00 price target on 2026-04-27. Recent price targets range from $50.00 to $118.00.What companies are similar to GPCR?
Notable peers in the same industry include MRK (Merck & Company Inc.), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare GPCR side-by-side with any of them on Quantisnow.How can I track GPCR on Quantisnow?
Quantisnow aggregates Structure Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GPCR to receive live email and push alerts on every new disclosure.